Friday, July 29, 2016

Juniper Pharma’s lidocaine vaginal gel data due in Q3

Juniper Pharma’s lidocaine vaginal gel data due in Q3

June 28, 2016 by · Leave a Comment 

Tweet Juniper Pharmaceuticals (NASDAQ:JNP) expects to report results in the third quarter from a Phase 2b clinical trial of its 10% lidocaine bioadhesive vaginal gel, COL-1077, a local anesthetic for pain from minimally invasive outpatient gynecological procedures. “There is no product like it on the market,” Frank Condella, president and CEO, says in an interview […]

Antibe to have Phase 2 pain data by third quarter

Antibe to have Phase 2 pain data by third quarter

June 21, 2016 by · Leave a Comment 

Tweet Antibe Therapeutics (OTCQB:ATBPF; TSX-V:ATE) expects to have data by the third quarter this year from a small Phase 2 study of its naproxen derivative, ATB-346, in patients with osteoarthritis in the knee. “ATB-346 was designed to deliver non-addictive pain relief with significantly less gastrointestinal and cardiovascular damage than is typically associated with the use […]

Lipocine advancing pipeline, PDUFA for oral TRT

Lipocine advancing pipeline, PDUFA for oral TRT

May 31, 2016 by · Leave a Comment 

Tweet With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing towards Phase 3 ready status this year. “We have a robust pipeline with a number of key milestones in 2016 besides the decision on […]

CRH Medical to consolidate GI anesthesia market

CRH Medical to consolidate GI anesthesia market

October 27, 2015 by · Leave a Comment 

Tweet With four acquisitions and a joint venture under its belt over the past 10 months, CRH Medical (NYSE MKT:CRHM; TSX:CRH) is in talks to continue consolidating the large and fragmented market of gastrointestinal (GI) anesthesia providers that serve the GI market. “Our goal is to be the leader in GI-focused anesthesia by leveraging the […]

XTL hopes to begin major lupus trial next year

XTL hopes to begin major lupus trial next year

July 22, 2014 by · Leave a Comment 

Tweet XTL Biopharmaceuticals (NASDAQ:XTLB; TASE:XTL) is aiming to begin a Phase 2b clinical trial in the first half of 2015 with its hCDR1 peptide to treat patients with systemic lupus erythematosus (SLE). “We are in the process of finalizing our trial design, approaching the FDA and hope to have feedback from the agency before the […]

Novadaq highlights game changer for the OR

Novadaq highlights game changer for the OR

October 16, 2012 by · Leave a Comment 

Tweet With adoption of its SPY imaging technologies growing in operating rooms across North America, Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has embarked on a long-term growth plan to image nerves and cancer cells with tissue-binding reagents that could represent a paradigm shift in the OR. “The future of the installed base of SPY technologies will include […]

Analysts up Novadaq price target

Analysts up Novadaq price target

September 27, 2012 by · Leave a Comment 

Tweet Piper Jaffray and RBC Capital Markets raised their price targets on Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) following the company’s upbeat presentations at its “analyst and investor day” meeting in New York. Piper Jaffray raised its target on “overweight-rated” Novadaq to $14 from $10 while RBC moved its target to $12 (Canadian) from $7 and maintained its “sector perform” rating. […]

Novadaq partnering strategy hits marketing milestone

Novadaq partnering strategy hits marketing milestone

January 17, 2012 by · Leave a Comment 

Tweet Novadaq Technologies (TSX:NDQ), a maker of real-time fluorescence imaging products for the operating room, reached a significant milestone earlier this month when it named MAQUET Cardiovascular as the exclusive distributor of its CO2 Heart Laser system in the U.S. “We have now completed our strategic agenda of partnering each one of our first four […]

Email Newsletters with Constant Contact
Google+